Imagine a way to cool down a patient's heart and brain almost instantly after a cardiac arrest to prevent permanent damage. Instead of air, this system uses a special breathable liquid that acts like a high-tech coolant for the lungs. It's like using a liquid-cooled radiator for the body to stop the 'fire' of reperfusion injury.
Post-cardiac arrest patients suffer from reperfusion injury, which significantly lowers survival rates. Current cooling methods may not be rapid or effective enough to protect the heart and brain immediately after resuscitation.
The Vent2Cool v2.1 medical device, which includes an improved liquid ventilator, a breathable circuit, and a recyclable breathable liquid called Liquid2Breathe.
If you are a medical device manufacturer dealing with the need for better post-resuscitation care — this project developed the Vent2Cool device that induces ultra-rapid protective cooling. This could establish a new gold standard for cardiac arrest centers.
If you are a logistics company dealing with high medical waste from respiratory support — this project developed a process for recycling the Liquid2Breathe breathable liquid. This reduces the environmental impact and lowers operational costs.
If you are an emergency service provider dealing with low survival rates in the field — this project developed a miniaturized liquid ventilation technology. This strengthens the ability to provide advanced respiratory support during pre-hospital care.
Based on available project data, Orixha is industrializing and miniaturizing the technology specifically to reduce costs and environmental impact, particularly through the reprocessing of the breathable liquid.
The project has identified the process for recycling the breathable liquid at both pilot and industrial scale.
Based on available project data, the project focuses on the development of the Vent2Cool v2.1 system and the Liquid2Breathe liquid, though specific licensing terms are not mentioned.
The goal is to obtain the CE Mark for the Vent2Cool device in 2026, with a commercial launch in the EU following that.
Two Vent2Cool v2 devices are expected to be delivered by the end of July 2024 for use in hospitals in Paris and Brussels by the end of the year.
The project is led by a single SME, ORIXHA, based in France. This 100% industry-led consortium indicates a strong drive toward commercialization rather than academic research, supported by a recent 4 M€ funding round from EIC Fund and BPI France.
Contact ORIXHA (FR) regarding Vent2Cool clinical validation
Contact us to explore partnerships for liquid ventilation applications.
